PTLA - Portola Could Have Big-Pharma Backed 'Blockbuster' Drug On Its Hands

Investment Thesis

Portola has experienced plenty of highs and lows and that has been reflected in a share price that has risen as high as $66 (in July 2017) but has since dwindled to just under $29. Arguably however, the company's prospects look better now that at any stage in its history. Of its portfolio, Andexxa, the anti-coagulant looks to be a potential blockbuster since it is has been heavily backed by big pharmas Johnson & Johnson, Pfizer and Bristol Myers Squibb, as the only FDA approved antidote for their market leading blood thinners Xarelto